Alkermes Announces Inaugural Alkermes Pathways APN Research Awards(TM) Program
MWN-AI** Summary
Alkermes plc (Nasdaq: ALKS) has announced its inaugural Alkermes Pathways APN Research Awards™ program, set to open for applications on March 16, 2026. This competitive grant initiative aims to support research efforts led by advanced practice nurses (APNs), specifically licensed psychiatric-mental health nurse practitioners (PMHNPs) who are engaged in clinical, academic, or community health settings and are focused on the treatment of schizophrenia and bipolar I disorder. The application window will remain open until June 1, 2026.
With grants of up to $10,000 available per project, the program underscores Alkermes' commitment to fostering innovative research in the field of mental health. Dr. Craig Hopkinson, Alkermes' Chief Medical Officer, emphasized the essential on-the-ground insights that psychiatric-mental health nurse practitioners bring to clinical care, highlighting how this program will expand support to those practitioners.
Professor Cynthia Handrup, Director of the PMHNP program at the University of Illinois Chicago and chair of the awards' review committee, expressed pride in collaborating with Alkermes to identify impactful projects that can enhance patient care through evidence-based research.
To qualify for the grants, applicants must hold a doctoral degree or work with a co-investigator or mentor who does. An independent review committee of esteemed researchers will evaluate applications based on their potential contributions to the field. For further details about eligibility and the application process, interested parties can visit Alkermes’ website.
Alkermes is a global biopharmaceutical company focused on developing innovative medicines for neuroscience-related conditions, with a strong portfolio dedicated to mental health disorders. The launch of the Alkermes Pathways APN Research Awards program represents a significant step in making research more aligned with the realities faced by patients and the healthcare providers who care for them.
MWN-AI** Analysis
Alkermes plc (Nasdaq: ALKS) recently announced the launch of its inaugural Alkermes Pathways APN Research Awards program, a strategic initiative aimed at enhancing the research landscape for psychiatric-mental health nurse practitioners. With individual grants of up to $10,000 available for projects that delve into schizophrenia and bipolar I disorder, this program not only embodies a commitment to advancing mental health treatment but also positions Alkermes as a thought leader in the field.
From a market perspective, this initiative could bolster Alkermes' reputation in the competitive biopharmaceutical landscape. Investors should view this move as a positive signal, highlighting the company’s dedication to innovation and collaboration with healthcare practitioners in the mental health domain. The involvement of licensed psychiatric-mental health nurse practitioners can infuse practical insights into clinical research, potentially leading to breakthroughs in therapeutic strategies.
Moreover, the grant program may create a ripple effect that enhances both community health outcomes and corporate social responsibility—factors that modern investors increasingly favor. This initiative complements Alkermes' existing portfolio, which focuses on innovative treatments for chronic conditions such as substance use disorders and serious mental illnesses, potentially enhancing long-term revenue streams.
As the application period nears, which runs from March 16 to June 1, 2026, investor interest may increase as clinical outcomes from funded projects emerge. For traders, this could present a unique opportunity to capitalize on potential stock price movements associated with Alkermes' increasing prominence in mental health research.
Consequently, maintaining a bullish outlook on Alkermes shares could be prudent, particularly for those interested in investing in the evolving mental health space. Continued monitoring of this program's developments will be essential in making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
— Competitive Grant Program to Offer Individual Grants of Up to $10,000 per Project —
— Inaugural Application Cycle Open to Licensed Psychiatric-Mental Health Nurse Practitioners Across Multiple Clinical Settings —
— Application Period to Run From March 16, 2026 Through June 1, 2026 —
Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its inaugural Alkermes Pathways APN Research Awards™ program on Monday, March 16, 2026. This competitive grant program is designed to support research conducted by advanced practice nurses (APN), specifically licensed psychiatric-mental health nurse practitioners who are actively engaged in clinical, academic and/or community health center settings and who possess a commitment to advancing treatment of schizophrenia or bipolar I disorder. The application period will run through June 1, 2026.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310230842/en/
“Psychiatric-mental health nurse practitioners bring deep, real?world insight from the front lines of care,” said Craig Hopkinson, M.D., Chief Medical Officer and Executive Vice President of Research and Development at Alkermes. “Over the last eight years, Alkermes has demonstrated a strong commitment to supporting early?career investigators through the Alkermes Pathways Research Awards ® program, helping to foster innovative research at pivotal stages in scientific careers. The launch of the Alkermes Pathways APN Research Awards program represents an important evolution of that commitment – expanding our support to advanced practice nurses whose unique perspectives can further inform clinical practice and deepen understanding of serious mental illness, including schizophrenia and bipolar I disorder. We are especially proud to launch this innovative program ahead of this spring’s International Society of Psychiatric Mental Health Nurses and Psych Congress Nurse Practitioner Institute annual meetings.”
“This program creates a meaningful opportunity for nurse practitioners to advance research questions grounded in clinical reality,” said Professor Cynthia Handrup, DNP, Director of the Psychiatric Mental Health Nurse Practitioner program at the University of Illinois Chicago and chair of the Alkermes Pathways APN Research Awards review committee. “I’m honored to work with Alkermes and the review committee to help identify projects with the potential to strengthen evidence and improve patient care.”
The inaugural Alkermes Pathways APN Research Awards program will offer grants in amounts up to $10,000 per project. To qualify, psychiatric-mental health nurse practitioners must be engaged in clinical, academic and/or community health settings and possess a doctoral degree (Ph.D, DNP, etc.) or have a co-investigator or mentor who does. Applications will be formally reviewed by an independent review committee comprised of prominent researchers in the relevant field. For more information on the Alkermes Pathways APN Research Awards program, including full eligibility criteria and how to apply for the inaugural edition of the program, visit http://www.alkermes.com/pathways-apn.
About Alkermes plc
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com .
Alkermes Pathways APN Research Awards™ is a registered service mark of Alkermes, Inc.
Alkermes Pathways Research Awards ® is a registered service mark of Alkermes, Inc. The Alkermes Pathways Research Awards logo is a service mark of Alkermes, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260310230842/en/
Alkermes Contacts:
For Investors: Sandy Coombs, +1 781 609 6377
For Media: Gretchen Murphy, +1 781 609 6419
FAQ**
How does the launch of the Alkermes Pathways APN Research Awards program align with Alkermes plc ALKS's overall strategic objectives in neuroscience and support for advanced practice nurses in mental health?
What specific criteria will the independent review committee use to evaluate the applications for the Alkermes Pathways APN Research Awards, and how does this reflect Alkermes plc ALKS's commitment to evidence-based research?
Can you elaborate on how funding from the Alkermes Pathways APN Research Awards program may influence future projects or initiatives within Alkermes plc ALKS's therapeutic areas, specifically schizophrenia and bipolar I disorder?
How does Alkermes plc ALKS plan to measure the impact and success of projects funded through the Alkermes Pathways APN Research Awards program on patient care and clinical practices in mental health settings?
**MWN-AI FAQ is based on asking OpenAI questions about Alkermes plc (NASDAQ: ALKS).
NASDAQ: ALKS
ALKS Trading
1.62% G/L:
$27.58 Last:
779,084 Volume:
$27.88 Open:
